Sarcoidosis (n=76) | |
Age at time of biopsy years | 43.98±12.22 |
Male sex | 42 (55) |
Ever smoker | 43 (59) |
White | 64 (84) |
Medication at time of biopsy | 6 (8) |
Third-line therapy# | 27 (36) |
COS group A/B (2 years follow-up) | 23/49 (32/68) |
COS group A/B (5 years follow-up) | 15/31 (33/67) |
Scadding stage at time biopsy (0/I/II/III/IV/unknown) | 5/19/28/9/10/5 (7/25/37/12/13/7) |
Extrapulmonary involvement | 54 (71) |
Skin | 18 (24) |
Eyes | 7 (9) |
Liver | 8 (11) |
Heart | 13 (17) |
Spleen | 3 (4) |
Bones | 4 (5) |
Nerve system | 15 (20) |
Central | 6 (8) |
Peripheral | 1 (1) |
Small fibre neuropathy | 10 (13) |
Data are presented as mean±sd or n (%). Scadding stages: 0: normal chest radiograph; I: BHL; II: BHL with pulmonary infiltrates; III: pulmonary infiltrates without BHL; IV: fibrosis. COS: clinical outcome status. #: third-line therapy consisted of infliximab use at follow-up.